Project:  “K+” “Biomarkers for Personalised Medicine in Common Metabolic Disorders’ It is generally agreed that a significant investment in the development of a new generation of biomarkers will be essential in order to enable more efficient and costeffective use of medical resources and to tackle the explosively increasing socioeconomiccosts associated with common metabolic disorders (up to 40% yearly) such as diabetes, cardiovascular and liver disease. Recognising this urgent imperative, the BioPersMed project will bring together an excellent group of industry and an internationally recognised interdisciplinary team of researchers in Graz who will pursue the systematic and integrated discovery, validation and proof-of-principle utilisation of biomarkers in metabolic disorders in the Areas of endocrinology, hepatology and vascular cardiology. Implementation will be highly structured and employ state-of-the-art analytical methods, data analysis and interpretation tools and advanced imaging methods for biomarker detection. A unique feature of BioPersMed is moreover its access to one of Europe’s largest Biobanks, which contains a broad spectrum of samples and associated structured data and thus provides a solid basis for biomarker discovery and translational research.

The Medical University of Graz coordinated the K-project proposal "BioPersMed" (BioBank) . Since this strategically important project is of great interest for the Medical University of Graz and further eight BioNanoNet partners, the preparation of the project proposal has been actively supported by the BioNanoNet (scientific preparation and formulation of the project proposal). The project proposal was positively evaluated and will be funded for 5 years (FFG COMET K-Project , BMVIT).

Project duration: 01/03/2010 - 02/03/2015

Project volume: approximately EUR 7.6 million

In addition to the Medical University of Graz the following BioNanoNet partners are project partners of BioPersMed: JOANNEUM RESEARCH, Graz University of Technology , Ludwig Boltzmann Institute for Traumatology , piCHEM , BioBank , Endocrinology and Nuclear Medicine, Center for Medical Research (ZMF), experimental Neurotraumatology.

For more information please visit

CBmed: Centre for Biomarker Research in Medicine

The yearly number of publications on biomarker research reached almost 50,000 in 2012 driven by the need of personalised medicine to provide the best possible medical care for each individual.

Medical biomarkers can serve as diagnostic, prognostic or predictive tools in clinical practice and show a promising role in pharmaceutical drug development to provide guidelines for the safe and effective use of targeted therapeutic drugs.

For more information please visit

DYNAMITE - Dynamic Network Arranged for Medical Device Innovation, Transfer & Exploitation

Dynamite is an interdisciplinary project initiative which develops new innovative services for SME on their way from the idea to market success. A network of medical technology, medicine, health sciences, economics and law is built up to enforce medical device companies and start up’s in Austria to increase their innovation output. This network will work as a One-stop-shop and opens access to customized Information, consulting, competencies and resources in a very unbureaucratically manner.

The first step within the project was to survey critical support demands of the branch, especially of SME, start up’s and founders. The service portfolio out of this initiative will range from very early interdisciplinary technology assessment and business planning over investigation of medical needs, reimbursement, regulatory affairs, quality- and risk management, IPR up to development, manufacturing and finally continuous innovation management for sustainable success.

The project Dynamite started in September 2013 will end by August 2015 - but the network initiative DYNAMITE will be subsequently developed and extended to increase innovation output of Austrian’s medical device industry.

For more details please visit the project website


The goal of the project "Lead Compound Screening" was to extract a class of specific lead substance(s) that is able to cross the blood-brain barrier and, if possible, can be used treat Alzheimers disease starting from a poorly-defined commercially available preparation composed of a mixture of many substances.

This organ preparation is nowadays prepared by enzymatic and thermal digestion of pig brain and is administered by intravenous injection. In order to achieve the project goal it will be attempted to fractionate the original preparation using analytical or preparative HPLC. As a result of this fractionation, various fractions are obtained that are simpler than the starting solution. The fractions exhibiting a neuroprotective activity will be selected by in vitro testing of neuroprotective activity.

These fractions will be further fractionated in an additional preparative HPLC Step to further reduce their complexity. In this way, using multiple HPLC runs, a reduction in complexity should be achieved allowing analytical investigation. So as to test the results obtained in vitro, at a specific timepoint an in vivo test of the neuroprotective activity should be carried out. Through this it should be ensured that the conclusions based on the in vitro results are relevant to the in vivo situation.

The LCS project was developed by the BioNanoNet and realised by JOANNEUM RESERACH, piCHEM, JSW Research and the University of Graz.


Nanodevice project coordinated by Finland is a European success story

The European Commission has labelled the NANODEVICE project, co-ordinated by the Finnish Institute of Occupational Health (FIOH), a success story. The project produced affordable measuring devices for determining the concentrations of nanoparticles in the air. The new NANOSOLUTIONS project is another potential success story, with its aim to create a completely new way of evaluating the health hazards of industrial nanoparticles.

Role of BioNanoNet: Andreas Falk, MSc. is a member of the international advisory group of the NANOSOLUTIONS project (IAG).

Project website:

For more information please view BioNanoNet News 2013/02.


The goal of this project was the development of a scientific tool capable of describing proteins and peptides in the interstitium so as to facilitate the in vivo measurement of key substances. Prerequisites were application flexibility, applicability to a wide range of proteins and peptides and outperformance of common immunochemical methods in terms of sensitivity.

The investigation of the interstitium (the extracellular fluid), which is the actual environment of every cell, is of great interest. The investigation of the corresponding key substances in the interstitium permits a more precise characterisation of the effect of medical agents and hormones.

It was planned in the course of the project to develop a scientific tool for the determination of proteins and peptides in the interstitium. Tissue fluid samples were obtained by means of open flow microperfusion, a method that seems to offer several advantages, in particular with respect to proteins and peptides. The resulting low sample volumes and concentrations required special analytical techniques. One analytical option considered was the development of an analysis method featuring nano-coupling techniques. In this case, nano-high pressure liquid chromatography (nano-HPLC) is coupled with mass spectrometry.


NanoTrust is a research project whose aim is an integrated analysis of the state-of-the-art knowledge concerning the possible risks that nanotechnology poses to human health and to the environment.

Duration/Awarding body  

The project has initial funding for three years (09/2007 – 08/2010) from the Federal ministry for transport, innovation and technology.

Cooperation partners

ITA (Institute of Technology Assessment) is building the literature database in close cooperation with the following two institutions: BioNanoNet Forschungsgesellschaft mbH and the Federal Environment Office (Umweltbundesamt).

Literature database

The literature database currently contains more than 1000 nanotechnology literature entries, devoted specifically to the topics of toxicology, environmental risks, risk management and technology assessment in relation to nanotechnology. This constitutes the knowledge base of the project and is being constantly expanded.  From the 1st of July 2008 onwards you will be able to access the literature database via a search interface and use it for research purposes. Literature that is freely available in the internet will be directly accessible via a provided link.

For more information please visit


more information coming soon!


Project-Title: „Magnetic Nanosensor Particles with Luminescence Upconversion Capability”

Application form in FWF/DFG „ERA-Chemistry Progamm“ 

BioNanoNet has supported the project by  placing project partners.

The joined research project aims to investigate novel nano sensor particles combining the following beneficial functionalities: Magnetism. This enables easy manipulation. The nanoparticles can be easily separated from the sample and collected at distinct positions by magnetic fields. Luminescence Up-conversion. This enables the generation of phosphorescence light in the visible range (blue, green, red) by excitation with near-infrared (NIR) light. This excitation and the up-conversion effect induce no luminescence background of the biological sample matter. Sensing. This enables the detecting chemical parameters and performing of bioassays.


Prototype development, validation and production of a TIRF based protein chip system for diagnosis of sepsis

In VALIPRO a TIRF based biochip system will be developed and validated that meets the mandatory borderlines of accuracy and precision for fast and reliable point-of-care (POC) diagnosis of sepsis.

The focus is on building up high quality biochip production, including the optical chip, the cover chip with the microfluidics, coating, spotting and in system biomarker assay.

For further details please visit

In VALIPRO ( we develop and validate a fully automated total internal reflectance fluorescence (TIRF) based biochip system. The compact and cost-efficient system diagnoses sepsis fast and accurate by use of multiparameter assays. New methods for self-calibration lead to highly accurate, precise and reliable diagnostic reports meeting point-of-care requirements and clinical regulations. The system can also be adapted for the use of other sets of parameters and applications. The sepsis chip is a simple and low cost cartridge offering an easy and hygienic handling. The cartridge is consisting of two injection moulded parts being merged with common connection technology:

  • The microfluidic chip or cover chip with channel structure manufactured by injection molding and
  • The optical chip with prism for light coupling containing the array of protein spots for biomarker detection.

The optical chip is made of an excellent optical polymeric material of high transparency and low autofluorescence at the excitation and detection wavelengths of interest. Onto the optical chip the capture molecules for biomarker detection are deposited. Each spot (about 100 μm) is arrayed in triplicate. In addition, guide dots, positive and negative controls are spotted. The biomarkers targeted comprise the inflammation markers C reactive protein (CRP), Interleukin-6 (IL-6) and procalcitonin (PCT), specific for bacterial infection. Though the relevant concentration ranges are extremely different, e.g. μg/ml for CRP, while pg/ml for IL- 6, they can all be measured with the same biochip system using a single platform and no multiple tests and other detection systems are necessary. The microfluidic part includes channels for sample transport, a waste chamber and a blood/plasma separation unit. The image shows the optical chip (25x75 mm) and the microfluidic chip which laser-welded together form the chip cartridge.

The biochip system also includes pre-analytical tests like the measurement of bilirubin. The sepsis chip system works with serum, plasma and whole blood. One drop of blood is sufficient for biomarker measurement. Each chip is self-calibrated. The time required for a complete multiplex assay from sample injection till data read-out is 20 min.

Consortium Partners:

1. AIT Austrian Institute of Technology GmbH Project coordination, assay development, validation 2. Fraunhofer Institute of Physical Measurement Techniques System and fluidic developments, chip design 3. micro resist technology GmbH Surface chemistry development 4. Payer International Technologies GmbH Injection molding, connection technology, chip design 5. MVZ Labor Seelig Clinical specifications, pre-analytics, validation.